Skip to main content

Galapagos Value Stock - Dividend - Research Selection

Galapagos NV

ISIN: BE0003818359, WKN: A0EAT9

Market price date: 08.01.2021
Market price: 84,08 EUR




Galapagos NV Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 08-03-2020
Cash flow
Net operating cash flow 3.208.620.000
Capital Expenditures -22.385.000
Free cash flow 3.186.234.880
Balance sheet
Total Equity 2.875.660.000
Liabilities & Shareholders equity 6.068.610.000
Income statement
Net income 149.845.000
Eps (diluted) 2,490
Diluted shares outstanding 60.178.700
Net sales/revenue 895.890.000

Fundamental ratios calculated on: 08-01-2021

Ratios
Key figures 08-01-2021
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI2,47
ROE47,39
Income statement
P/E33,77
Div. Yield0,00%
P/B0,00
P/S5,65


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolGLPG.AS
Market Capitalization6.136.840.704,00 USD
CountryBelgium
IndicesAEX 25
SectorsChemistry
Raw Data SourceIFRS in Millionen EUR
Stock Split
Internetwww.glpg.com


Description of the company

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn\'s disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.glpg.com